Literature DB >> 21813471

Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.

Erwin Daniel Brenndörfer1, Anette Brass, Jonas Söderholm, Lars Frelin, Soo Aleman, Johannes Georg Bode, Matti Sällberg.   

Abstract

BACKGROUND: The non-structural (NS) 3/4A protease/helicase of the hepatitis C virus is known to modulate signalling pathways in the infected hepatocyte by cleaving CARD adaptor inducing IFNβ (Cardif), T-cell protein tyrosine phosphatase (TC-PTP) and TIR domain-containing adaptor inducing IFNβ (TRIF), but the effects of NS3/4A in vivo still remain unclear. AIM: To investigate the influence of NS3/4A on intracellular and intercellular signalling in vivo by analysing the intrahepatic inflammatory response of naïve, lipopolysaccharide (LPS)/D-galactosamine (D-galN) or tumour necrosis factor-α (TNFα)/D-galN-treated NS3/4A-transgenic (Tg) mice.
METHODS: The intrahepatic immunity of naïve and LPS/D-galN- or TNFα/D-galN-treated NS3/4A-Tg mice was determined using western blot, ELISA, real-time PCR, flow cytometry and survival monitoring. The injection of cytokines or antibodies against signalling components was performed to analyse the relevance of the respective pathways for the investigated issues. A Tg mouse lineage expressing an inactivated NS3/4A protease (NS3/4A(Ile1073Ala)-Tgs) was generated to examine if protective effects were NS3/4A protease dependent.
RESULTS: The activation of hepatic signal transducer and activator of transcription 1 and 2 was impaired in NS3/4A-Tg mice after treatment with LPS/D-galN or TNFα/D-galN. This was paralleled by a reduction in hepatic interferon-γ (IFNγ). Reconstitution of IFNγ reverted the resistance to LPS/TNFα in NS3/4A-Tg mice. Subsequently, blocking IFNγ in vivo rendered wild-type mice resistant against treatment with LPS/TNFα. A new Tg mouse expressing an inactivated NS3/4A protease had the same phenotype as wild-type mice with respect to hepatic IFNγ levels and sensitivity to LPS/d-galN. Finally, the chemokine profile was altered in the NS3/4A-Tg mice towards an anti-inflammatory state, which helps to explain the altered immune cell subsets and reduction in hepatic IFNγ production.
CONCLUSIONS: Our data demonstrate that the NS3/4A protease reduces the intrahepatic production of IFNγ and alters TNFα-mediated effects, thereby impairing the hepatic inflammatory response. This may contribute to viral persistence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813471     DOI: 10.1136/gut.2010.232116

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.

Authors:  Ravi Rajagopalan; Lin Pan; Caralee Schaefer; John Nicholas; Sharlene Lim; Shawn Misialek; Sarah Stevens; Lisa Hooi; Natalia Aleskovski; Donald Ruhrmund; Karl Kossen; Lea Huang; Sophia Yap; Leonid Beigelman; Vladimir Serebryany; Jyanwei Liu; Srikonda Sastry; Scott Seiwert; Brad Buckman
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 2.  HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers.

Authors:  Jessica Proulx; Maria Ghaly; In-Woo Park; Kathleen Borgmann
Journal:  Biomedicines       Date:  2022-03-25

Review 3.  Virus-related liver cirrhosis: molecular basis and therapeutic options.

Authors:  Ji Lin; Jian-Feng Wu; Qi Zhang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 4.  Hepatitis C virus infection: looking for interferon free regimens.

Authors:  J González-Moreno; A Payeras-Cifre
Journal:  ScientificWorldJournal       Date:  2013-04-09

5.  Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Authors:  Ola Weiland; Gustaf Ahlén; Helmut Diepolder; Maria-Christina Jung; Sepideh Levander; Michael Fons; Iacob Mathiesen; Niranjan Y Sardesai; Anders Vahlne; Lars Frelin; Matti Sällberg
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

Review 6.  The role of chemokines in hepatitis C virus-mediated liver disease.

Authors:  Anette Brass; Erwin Daniel Brenndörfer
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

7.  Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Authors:  Fredrik Holmström; Margaret Chen; Anangi Balasiddaiah; Matti Sällberg; Gustaf Ahlén; Lars Frelin
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.